Motoko Tanaka
Overview
Explore the profile of Motoko Tanaka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
1123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nakano T, Watanabe H, Imafuku T, Tokumaru K, Fujita I, Arimura N, et al.
Toxins (Basel)
. 2021 Dec;
13(12).
PMID: 34941746
Activation of mTORC1 (mechanistic target of rapamycin complex 1) in renal tissue has been reported in chronic kidney disease (CKD)-induced renal fibrosis. However, the molecular mechanisms responsible for activating mTORC1...
12.
Hirata K, Ikeda T, Watanabe H, Maruyama T, Tanaka M, Chuang V, et al.
Toxins (Basel)
. 2021 Nov;
13(11).
PMID: 34822595
The binding of drugs to plasma protein is frequently altered in certain types of renal diseases. We recently reported on the effects of oxidation and uremic toxins on the binding...
13.
Kato H, Watanabe H, Imafuku T, Arimura N, Fujita I, Noguchi I, et al.
J Cachexia Sarcopenia Muscle
. 2021 Oct;
12(6):1832-1847.
PMID: 34599649
Background: Sarcopenia with chronic kidney disease (CKD) progression is associated with life prognosis. Oxidative stress has attracted interest as a trigger for causing CKD-related muscular atrophy. Advanced oxidation protein products...
14.
Yamamoto A, Wada H, Ichkawa Y, Tanaka M, Tashiro H, Shiraki K, et al.
J Clin Med
. 2021 Jul;
10(13).
PMID: 34203210
Disseminated intravascular coagulation (DIC) is induced by excess activation coagulation, and activated platelets are also involved in pathogenesis. Therefore, plasma levels of soluble C-type lectin-like receptor 2 (sCLEC-2), a new...
15.
Imafuku T, Watanabe H, Oniki K, Yoshida A, Kato H, Nakano T, et al.
Diabetes Care
. 2021 Apr;
44(6):e115-e117.
PMID: 33905348
No abstract available.
16.
Watanabe H, Fujimura R, Hiramoto Y, Murata R, Nishida K, Bi J, et al.
Sci Rep
. 2021 Apr;
11(1):7953.
PMID: 33846468
The molecular mechanism for acute kidney injury (AKI) and its progression to chronic kidney disease (CKD) continues to be unclear. In this study, we investigated the pathophysiological role of the...
17.
Ichkawa Y, Wada H, Ezaki M, Tanaka M, Hiromori S, Shiraki K, et al.
Clin Appl Thromb Hemost
. 2020 Dec;
26:1076029620973084.
PMID: 33347372
D-dimer is a biomarker of thrombosis and recently been considered to predict a poor outcome in patients with infectious diseases. Plasma D-dimer levels were measured in critically ill patients to...
18.
Sugiyama S, Yoshida A, Hieshima K, Kurinami N, Jinnouchi K, Tanaka M, et al.
J Clin Med Res
. 2020 Nov;
12(11):724-733.
PMID: 33224374
Background: Renal function deterioration accompanied by an acute decrease in estimated glomerular filtration rate (eGFR) was observed early after starting sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapy. It is unclear how much...
19.
Sumiya K, Matsunaga T, Tanaka M, Mochizuki S, Sakurai K
Biomacromolecules
. 2020 Nov;
21(12):4823-4834.
PMID: 33186018
Oligo-deoxyadenylic acid (dA) forms a novel 1:2 triple-helix with β-1,3-d-glucan schizophyllan (SPG). We found that dA meticulously selects the most suitable length of SPG to bind; for example, dA only...
20.
Imafuku T, Tanaka M, Tokunaga K, Miyamura S, Kato H, Tanaka S, et al.
Biol Pharm Bull
. 2020 Oct;
43(10):1583-1590.
PMID: 32999168
Chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT) have an increased risk of cardiovascular disease (CVD). Cinacalcet is a calcimimetic that permits impaired endothelial functions to be recovered via...